OverviewChartNewsTraderScreen

Citi Put 88 NVSEF 20.06.2024/  DE000KJ0EE70  /

EUWAX
2024-04-09  9:05:59 AM Chg.- Bid10:00:17 PM Ask10:00:17 PM Underlying Strike price Expiration date Option type
0.420EUR - -
Bid Size: -		 -
Ask Size: -		 Novartis AG 88.00 - 2024-06-20 Put
GlobeNewswire 3:31 PM US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 2:00 PM ACELYRIN, INC. Announces Leadership Transition
GlobeNewswire 1:00 PM Royalty Pharma Reports First Quarter 2024 Results
GlobeNewswire 1:00 PM Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radioph...
GlobeNewswire 12:45 PM Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
GlobeNewswire 05-08 Erasca Reports First Quarter 2024 Business Updates and Financial Results
TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
GlobeNewswire 02-28 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...